IMPROVED PREDICTIVE VALUE FOR SUSTAINED IMMUNE CONTROL IN PEGINTERFERON ALFA-2A (40KD) (PEGASYS)-TREATED HBEAG-POSITIVE PATIENTS USING COMBINED HBSAG AND HBV DNA LEVELS AT WEEK 24

被引：2
|
作者：
Piratvisuth, T. [1 ]
Chan, H. L. Y. [2 ]
Marcellin, P. [3 ,4 ]
Wat, C. [5 ]
Regep, L. [6 ]
Messinger, D. [7 ]
Kapprell, H. -P. [8 ]
Lu, Z. M. [9 ]
Luo, K. X. [10 ]
机构：
[1] Prince Songkla Univ, Songklanagarind Hosp, NKC Inst Gastroenterol & Hepatol, Dept Internal Med, Hat Yai, Thailand
[2] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[3] Univ Paris Diderot, Serv Hepatol, Clichy, France
[4] Univ Paris Diderot, INSERM CRB3 U773, Clichy, France
[5] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[6] F Hoffmann La Roche, Basel, Switzerland
[7] IST GmbH, Mannheim, Germany
[8] Abbott GmbH & Co KG, Wiesbaden, Germany
[9] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China
[10] So Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)60551-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
538
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [1] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [2] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
  • [3] Predictors of histologic improvement and relationship between sustained response and histology in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®)
    Lau, GK
    Cooksley, G
    Marcellin, P
    Piratvisuth, T
    Hadziyannis, S
    Farci, P
    Fried, MW
    Bonino, F
    Jin, R
    Button, P
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 587A - 587A
  • [4] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [5] HBeAg and HBV DNA kinetics in HBsAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)
    Fried, M. W.
    Liaw, Y. F.
    Luo, K. X.
    Lau, G. K. K.
    Piratvisuth, T.
    Cooksley, G.
    Marcellin, P.
    Flisiak, R.
    Popescu, M.
    Button, P.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S183 - S183
  • [6] Predicting response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B
    Cooksley, Graham
    Chow, Wan Cheng
    Piratvisuth, Teerha
    Lau, George K. K.
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A108 - A108
  • [7] Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)
    Piratvisuth, T.
    Lau, G. K. K.
    Marcellin, P.
    Chow, W. C.
    Cooksley, G.
    Fried, M. W.
    Paik, S. W.
    Liaw, Y. F.
    Popescu, M.
    Button, P.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S23 - S23
  • [8] ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a (40KD) (PEGASYS®) are not necessary for a significant response to therapy.
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2003, 38 (04) : 724A - 724A
  • [9] HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Drakoulis, C.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S287
  • [10] Enhanced pharmacokinetics (PK) and pharmacodynamics (PD) of peginterferon alfa-2a (40KD) (PEGASYS®) vs conventional interferon alfa-2a in HBeAg-positive chronic hepatitis B (CHB)
    Choudhury, S
    Wang, YJ
    Thongasawat, S
    Minde, Z
    Chan, WY
    Piratvisuth, T
    Yuan, R
    ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER MEETING 2002, 2002, : 95 - 100
12345